HTSUY (Hisamitsu Pharmaceutical Co) Total Receivables: $315 Mil (As of Nov. 2025)


HTSUY Hisamitsu Pharmaceutical Co Inc HTSUY
72 GF Score
Price $2.94
GF Value $2.39
Valuation Significantly Undervalued
View Full Analysis

What is Hisamitsu Pharmaceutical Co Total Receivables?

Hisamitsu Pharmaceutical Co HTSUY 72 Total Receivables is $315 Mil as of Nov. 2025. GuruFocus rates HTSUY with a GF Score™ of 72/100 and a GF Value™ of $2.39 (Significantly Undervalued).

Hisamitsu Pharmaceutical Co's Total Receivables for the quarter that ended in Nov. 2025 was $315 Mil.


Hisamitsu Pharmaceutical Co Total Receivables Related Terms


Hisamitsu Pharmaceutical Co Total Receivables Historical Data

* Premium members only.

The historical data trend for Hisamitsu Pharmaceutical Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hisamitsu Pharmaceutical Co Total Receivables Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 334.02 300.75 288.99 311.56 364.82

Hisamitsu Pharmaceutical Co Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 311.56 327.44 332.04 314.55 364.82
HTSUY
72GF Score
Hisamitsu Pharmaceutical Co Inc HTSUY
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hisamitsu Pharmaceutical Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $315 Mil mean?
Hisamitsu Pharmaceutical Co (HTSUY) has a Total Receivables of $315 Mil as of Nov. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Hisamitsu Pharmaceutical Co and its competitors.
Is Hisamitsu Pharmaceutical Co's Total Receivables too high?
Hisamitsu Pharmaceutical Co's current Total Receivables is $315 Mil. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Total Receivables compare to ESPR and AMPH?
Hisamitsu Pharmaceutical Co's Total Receivables of $315 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Hisamitsu Pharmaceutical Co and its competitors. Hisamitsu Pharmaceutical Co's current Total Receivables is $315 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co (HTSUY) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.39, compared to a current price of $2.94 — trading 23% above its estimated fair value. The current Total Receivables is $315 Mil. Hisamitsu Pharmaceutical Co's overall GF Score™ is 72/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (HTSUY), the current Total Receivables is $315 Mil as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hisamitsu Pharmaceutical Co (HTSUY) Overvalued in 2026?

Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued. The current stock price of $2.94 is trading 23% above its estimated GF Value™ of $2.39. GuruFocus considers Hisamitsu Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for HTSUY:

  • Total Receivables: $315 Mil
  • GF Value™: $2.39 vs. price of $2.94 (23% above fair value)
  • GF Score™: 72/100

No single metric tells the full story. See the HTSUY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hisamitsu Pharmaceutical Co Business Description

Address 408 Tashiro Daikancho, Saga Prefecture, Tosu, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
72GF Score

Get the complete analysis for HTSUY

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.94
Price
$2.39
GF Value